Physician profile
Reed Stone
NPI 1881706018
$7,826.94
in general payments reported to CMS, 2019-2025
52 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $709 · 2021: $1,409 · 2022: $1,304 · 2023: $883 · 2024: $1,238 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,542.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $784.85 | 2020-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $566.26 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Genzyme Corporation | $527.52 | 2019-2025 | |
| Biogen, INC. | $489.81 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Teva Pharmaceuticals USA, INC. | $486.14 | 2019-2023 | Ajovy |
| Emd Serono, INC. | $475.43 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $453.17 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $376.21 | 2019-2024 | |
| Neurelis, INC. | $322.56 | 2020-2025 | Valtoco |
| Eisai INC. | $284.42 | 2021-2025 | |
| Celgene Corporation | $232.91 | 2021-2022 | |
| Genentech USA, INC. | $207.63 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Almatica Pharma LLC | $200.52 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $196.18 | 2021-2025 | Fycompa |
| Mallinckrodt Hospital Products INC. | $195.88 | 2022-2025 | Acthar |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.